PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2023-02-18 (2)

Date Title Company
18-Feb-2023 Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy Businesswire